Retatrutide
Choose delivery frequency and start your subscription from your cart — combine multiple products into one subscription if they ship on the same schedule. Free shipping, always. Cancel anytime — one click in your account, no calls, no retention offers.
Concentration calculator
Research summary
Retatrutide is a synthetic peptide engineered as a triple agonist of the GLP-1, GIP, and glucagon receptors —three hormone pathways involved in appetite and energy metabolism. It's an investigational molecule studied in randomized, placebo-controlled human clinical trials for obesity, not approved for any use as of this writing.
In a Phase 2 trial published in the New England Journal of Medicine, participants on the highest studied dose lost a mean of 24.2% of body weight by week 48 versus a small change on placebo, with most high-dose participants achieving at least 15% weight loss and the trial noting participants hadn't yet reached a weight plateau when it ended. These are results from a supervised clinical trial in human subjects with obesity, not findings describing unsupervised use.
Sources: NEJM, 2023 (NEJMoa2301972). Findings from published research —not a claim about this product, and not evidence of safety or effectiveness for human use.
Decoding the Benefits
- Targets three separate metabolic hormone pathways at once, a broader mechanism than most single-pathway weight-loss peptides.
- The highest-dose group hadn't even plateaued by the end of the study — suggesting results may extend further with more time.
- The large majority of high-dose participants cleared the 15% weight-loss mark.
Customer reviews
More in Metabolic
